Prakt. lékáren. 2018; 14(2): 63-66 | DOI: 10.36290/lek.2018.058

Iatrogenic, drug‑induced depressions

Jana Hroudová
Psychiatrická klinika, 1. lékařská fakulta, Univerzita Karlova a VFN v Praze
Farmakologický ústav, 1. lékařská fakulta, Univerzita Karlova a VFN v Praze
Oddělení klinické farmakologie, VFN v Praze

Pharmacologically induced depressions represent complications of patients’ health and worsen their prognoses. A big range ofdrugs has a depressogenic potential: antiparkinsonian drugs (L-dopa, amantadine), anticonvulsants (topiramate, phenobarbital),disease-modifying drugs used for multiple sclerosis (interferon-α, glatiramer acetate), drugs used in oncology (interleukins,procarbazine, vincristine), antihypertensive drugs (methyldopa), corticoids, benzodiazepines, opioid analgesics (pethidine), antibiotics(ciprofloxacin), antiviral drugs etc. This review summarizes the most common drug-induced depressions and possibilitiesof their solutions.

Keywords: drug‑induced depresssion, adverse drug effects

Received: January 18, 2018; Accepted: January 18, 2018; Published: June 20, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hroudová J. Iatrogenic, drug‑induced depressions. Praktické lékárenství. 2018;14(2):63-66. doi: 10.36290/lek.2018.058.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cove-Smith JR, Kirk CA. CNS-related side-effects with metoprolol and atenolol. Eur J Clin Pharmacol, 1985. 28 Suppl: p. 69-72. Go to original source... Go to PubMed...
    2. Ahmed AI, van Mierlo P, Jansen P. Sleep disorders, nightmares, depression and anxiety in an elderly patient treated with low-dose metoprolol. Gen Hosp Psychiatry, 2010. 32(6): p. 646.e5-7. Go to original source... Go to PubMed...
    3. Liu X, et al. Impact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disorders. Drug Des Devel Ther, 2017. 11: p. 305-312. Go to original source... Go to PubMed...
    4. Tyrlíková I, Brázdil M. Nežádoucí účinky nových antiepileptik, Neurologie pro praxi, 2007. 2: p. 76-78.
    5. Rocamora R, et al. Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: A prospective multicenter study. Epilepsy Behav, 2017. 79: p. 87-92. Go to original source... Go to PubMed...
    6. Ossowska K, Lorenc-Koci E. Depression in Parkinson's disease. Pharmacol Rep, 2013. 65(6): p. 1545-1557. Go to original source... Go to PubMed...
    7. Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med, 2006. 354(9): p. 899-910. Go to original source... Go to PubMed...
    8. Celano CM, et al. Depressogenic effects of medications: a review. Dialogues Clin Neurosci, 2011. 13(1): p. 109-125. Go to original source...
    9. Leonard BE. The HPA and immune axes in stress: the involvement of the serotonergic system. Eur Psychiatry, 2005. 20 Suppl 3: p. S302-306. Go to original source... Go to PubMed...
    10. Young, EA, et al. Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology, 2007. 32(7): p. 843-853. Go to original source... Go to PubMed...
    11. Choi SH, et al. Psychological side-effects of clomiphene citrate and human menopausal gonadotrophin. J Psychosom Obstet Gynaecol, 2005. 26(2): p. 93-100. Go to original source... Go to PubMed...
    12. Thoa NB, et al. Inhibition of release of dopamine-hydroxylase and norepinephrine from sympathetic nerves by colchicine, vinblastine, or cytochalasin-B (hypogastric nerve stimulation-exocytosis-microtubules-microfilaments-guinea pig). Proc Natl Acad Sci U S A, 1972. 69(2): p. 520-522. Go to original source... Go to PubMed...
    13. Capuron L, et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology, 2001. 26(8): p. 797-808. Go to original source... Go to PubMed...
    14. Manian FA, Stone WJ, Alford RH. Adverse antibiotic effects associated with renal insufficiency. Rev Infect Dis, 1990. 12(2): p. 236-249. Go to original source... Go to PubMed...
    15. Ilgin S, et al. Ciprofloxacin-induced neurotoxicity: evaluation of possible underlying mechanisms. Toxicol Mech Methods, 2015. 25(5): p. 374-381. Go to original source... Go to PubMed...
    16. van Riemsdijk MM, et al. Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther, 2002. 72(3): p. 294-301. Go to original source... Go to PubMed...
    17. Meier CR, Wilcock K, Jick SS. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf, 2004. 27(3): p. 203-213. Go to original source... Go to PubMed...
    18. Beste LA, et al. Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clin Gastroenterol Hepatol, 2010. 8(11): p. 972-978. Go to original source... Go to PubMed...
    19. De La Garza R, Asnis GM. The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus. Brain Res, 2003. 977(1): p. 70-79. Go to original source... Go to PubMed...
    20. Anthenelli RM, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet, 2016. 387(10037): p. 2507-2520. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.